Dyne Therapeutics Upsizes Offering to $375M, Prices at $20.50 — a 14% Discount to Last Close
DYN has more than doubled off its 52-week low of $8.88 on elevated volume (4.7× avg).
Summary
Dyne Therapeutics priced an upsized $375.2 million follow-on offering at $20.50 per share, a 14% discount to the last close, raising capital to fund its neuromuscular pipeline through Q2 2028.
Key Events · Financing and Capital Events · DYN
-
Upsized Offering Priced at Discount
Dyne sold 18.3 million shares at $20.50, a 14% discount to the prior close, raising $375.2 million — up from the $300 million initially filed yesterday. Underwriters have a 30-day option for 2.745 million additional shares.
-
Dilution Impact
The offering increases shares outstanding by approximately 11% (to ~183.8 million), with immediate dilution of $13.87 per share for new investors based on pro forma net tangible book value of $6.63.
-
Use of Proceeds
Net proceeds of ~$352 million, combined with existing cash and a recent $50 million debt draw, extend the cash runway into Q2 2028, funding z-rostudirsen and z-basivarsen development, manufacturing, and commercial infrastructure.
-
Strategic Timing
The offering follows the FDA's acceptance of the z-rostudirsen BLA with Priority Review (PDUFA January 21, 2027) and the initiation of Phase 3 trials for both lead programs, positioning the company to fund a potential commercial launch.
Analysis · DYN · Life Sciences
Dyne Therapeutics priced its follow-on offering at $20.50 per share, a 14% discount to yesterday's close of $23.83, raising $375.2 million before the overallotment option. The deal was upsized from the $300 million initially filed yesterday, reflecting strong demand but also the discount needed to clear the market. Net proceeds of approximately $352 million extend the cash runway into Q2 2028, funding the commercial launch of z-rostudirsen (PDUFA January 2027) and the Phase 3 programs for z-basivarsen. The discount is notable but not distressed — the company is capitalizing on a recent BLA acceptance and Priority Review to secure a war chest ahead of potential approval.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $23.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $8.88 to $25.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.